Darunavir Ethanolate CAS# 635728-49-3 is a second-generation protease inhibitor (PIs), designed specifically to overcome problems with the older agents in this class, such as indinavir. Darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including strains from treatment-experienced patients with multiple resistance mutations to PIs. Darunavir is always used in combination with ritonavir (Norvir) and other anti-HIV medicines.
We are proud to present to you this product for the research and development of new formulations in the Anti-Retroviral / Anti-HIV therapeutic category.
It is in our best interest to promote and to further your ongoing research and/or product development efforts. All the enumerated API’s are produced strictly following cGMP guidelines and regulations. It would be our pleasure to supply you with Darunavir Ethanolate, as well as any other new molecules that may be required.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.